alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.3830 Salicylate test system. ( a ) *Identification.* A salicylate test system is a device intended to measure salicylates, a class of analgesic, antipyretic and anti-inflammatory drugs that includes aspirin, in human specimens. Measurements obtained by this device are used in diagnosis and treatment of salicylate overdose and in monitoring salicylate levels to ensure appropriate therapy.
( b ) *Classification.* Class II.
NASA LogoNTRSNTRS - NASA Technical Reports ServerSearchmore_vertCollectionsAboutNewsHelpLogin Back to ResultsAcoustic Testing of a High-Tip-Speed Fan with Bypass-Duct Liners - OverviewUnder a pair of Space Act Agreements between NASA and Honeywell Aerospace, a model-scale (22 in.-diameter fan) acoustic wind tunnel test was carried out in the fall of 2014 in the NASA Glenn Research Center 9- by 15-Foot Low-Speed Wind Tunnel. The goal was to obtain acoustic pressure measurements for far-field, inlet and exit rotating rake, and in-duct microphone locations. This supersonic-tip-speed fan was tested in three bypass duct configurations: hard-wall, traditional liner, and advanced multiple-degree-of-freedom. Limited aerodynamic data was collected to verify the expected operating conditions. Preliminary analysis of the acoustic data finds it suitable for use in evaluating current NASA and Honeywell Aerospace acoustic tools and liner design practices. This report provides an overview of the test and some preliminary findings.Document ID20190025444Acquisition SourceGlenn Research CenterDocument TypeTechnical Memorandum (TM)AuthorsMiller, Christopher J.*(NASA Glenn Research Center Cleveland, OH, United States)*Stephens, David B.*(NASA Glenn Research Center Cleveland, OH, United States)*Sutliff, Daniel L.*(NASA Glenn Research Center Cleveland, OH, United States)*Date AcquiredMay 31, 2019Publication DateMay 1, 2019Subject CategoryAcousticsAerodynamicsReport/Patent NumberGRC-E-DAA-TN66525NASA/TM-2019-220162E-19678Funding Number(s)WBS: 081876.02.03.06Distribution LimitsPublicCopyrightWork of the US Gov. Public Use Permitted.Technical ReviewSingle ExpertAvailable DownloadsNameType20190025444.pdfSTIcloud_downloadcontent_copyvisibilityRelated RecordsThere are no records associated with this record.visibility_offNo Preview Available
 No Fear Act | Freedom of Information Act | Office of the Inspector General | Agency Financial ReportsNASA Web Privacy Policy and Important Notices | NASA Guidelines for Quality of InformationDisclaimers, Copyright, Terms of Use | Accessibility | NASA OCIO | USA.gov | NASA.govContact Us | Site MapSTI LogoNASA Official: JoAnne R. Calhoun Site Curator: STI Compliance and Distribution Services Last Modified: September 12, 2024
Order entered March 6, 2013

In The

Court of Appeals 

Fifth District of Texas at Dallas 

No. 05-12-01559-CV

CHERRY PETERSEN LANDRY ALBERT L.L.P., Appellant

V.

ERWIN CRUZ, M.D., Appellee

On Appeal from the 101st Judicial District Court

Dallas County, Texas

Trial Court Cause No. 10-16274

ORDER

The Court has before it appellant’s March 1, 2013 second unopposed motion for 

extension of time to file brief of appellant. The Court GRANTS the motion and ORDERS

appellant to file its brief by April 8, 2013. No further extensions will be granted without a 

showing of exceptional circumstances.

/s/ ELIZABETH LANG-MIERS 

JUSTICE
§ 526.363 Cephapirin benzathine. ( a ) *Specifications.* Each single-dose, 10-milliliter syringe contains 300 milligrams cephapirin activity (as cephapirin benzathine).
( b ) *Sponsor.* See No. 000010 in § 510.600(c) of this chapter.
( c ) *Related tolerances.* See § 556.115 of this chapter.
( d ) *Conditions of use in dry cows* — ( 1 ) Amount . Infuse the contents of one syringe (300 mg cephapirin activity) into each quarter following last milking, but no later than 30 days before calving.
( 2 ) *Indications for use.* For the treatment of mastitis caused by susceptible strains of *Streptococcus agalactiae* and *Staphylococcus aureus,* including penicillin-resistant strains.
( 3 ) *Limitations.* For use in dry cows only. Not to be used within 30 days of calving. Milk from treated cows must not be used for food during the first 72 hours after calving. Animals infused with this product must not be slaughtered for food until 42 days after the latest infusion. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[43 FR 37174, Aug. 22, 1978, as amended at 53 FR 27851, July 25, 1988; 73 FR 12262, Mar. 7, 2008; 75 FR 10168, Mar. 5, 2010; 76 FR 17338, Mar. 29, 2011; 86 FR 13186, Mar. 8, 2021; 88 FR 16549, Mar. 20, 2023]
38768.

#### MINCEY *et al.*v. THE STATE.

Carlisle, Judge.

1. The defendants were convicted of burglary. An accomplice who pleaded guilty testified that the defendants participated with him in the commission of the crime. The other evidence was substantially that the officers apprehended the defendants in the vicinity of the Candler County Training School late at night in an automobile in which they also found the stolen property, consisting of butter, cheese and sausage. Investigation revealed tracks identified as tracks of one of the defendants and of the accomplice leading into the kitchen of the training school from which the stolen property was shown to have been taken. The circumstantial evidence introduced in corroboration with the testimony of the accomplice was sufficient to lead at least to the inference that the defendants were guilty of the crime charged. It was not essential that such evidence exclude every other reasonable hypothesis save the guilt of the accused. *Price v. State,*208 Ga. 695 (3a) (69 S. E. 2d 253). The evidence authorized the verdict of guilty.

2. Grounds 4, 6, 7 and 8 of the motion for a new trial complain of the failure of the court to charge the jury “sufficiently on the question of intent as to movant William Joiner”; “sufficiently on confessions”; “upon the defense set up by the defendant William Joiner and the law appropriate to the defense . . . that he had not committed the crime of burglary and had not in fact broken into or entered the school and had not committed a larceny or felony therein nor any other crime”; and, “in not instructing the jury as to the form of their verdict if they should find one or both defendants not guilty.” Such assignments of error are not sufficient to present any question for decision by the trial court and are “too general to apprize the reviewing court of the nature and character of the particular legal principle which the exceptor complains was omitted from the charge.” *Spence v. Morrow,*128 Ga. 722 (1) (58 S. E. 356); *Paulk v. Speer,*143 Ga. 621 (2) (85 S. E. 867); *Winford, v. State,*213 Ga. 396 (99 S. E. 2d 120); *Atlantic Coast Line R. Co. v. Godard,*93 Ga. App. 671 (5) (92 S. E. 2d 626).

3. The portion of the charge excepted to in ground 5 of the motion was pertinent and legal, and it was not rendered *473erroneous, as contended therein, by the failure of the trial court to charge in the same connection some other pertinent and legal proposition. *Belvin v. Beard,*77 Ga. App. 681 (2) (49 S. E. 2d 546); *Burton & Class v. Connell,*84 Ga. App. 106 (2) (65 S. E. 2d 620); *City of Decatur v. Robertson,*85 Ga. App. 747, 750 f3) (70 S. E. 2d 135).

Decided April 5, 1961.

*George H. Lane,*for plaintiffs- in error.

*Walter C. McMillan, Jr., Solicitor-General, W. H. Lanier, Solicitor-General Emeritus,*contra.

*Judgment affirmed.*

*Townsend, P.J., Frankum and Jordan, JJ., concur.*
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM PIMCO
ADVISORS HOLDINGS L.P. FINANCIAL STATEMENTS AND IS QUALIFIED IN ITS ENTIRETY BY
REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1998
<PERIOD-START>                             JAN-01-1998
<PERIOD-END>                               SEP-30-1998
<CASH>                                          22,579
<SECURITIES>                                         0
<RECEIVABLES>                                   30,516
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                53,095
<PP&E>                                               0
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                                 521,184
<CURRENT-LIABILITIES>                           53,305
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                       467,879<F1>
<OTHER-SE>                                           0
<TOTAL-LIABILITY-AND-EQUITY>                   521,184
<SALES>                                              0<F2>
<TOTAL-REVENUES>                                66,440
<CGS>                                                0<F2>
<TOTAL-COSTS>                                        0<F2>
<OTHER-EXPENSES>                                10,721
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                 55,719
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                             55,719
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                    55,719
<EPS-PRIMARY>                                     1.18
<EPS-DILUTED>                                     1.11
<FN>
<F1>Entity is a partnership. Amount shown represents Partners' Capital.
<F2>The partnership is in the service business and has no sales or cost of good
sold on tangible products.
</FN>
        

</TABLE>
EXHIBIT 32.1

 

CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

This certification is provided pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and accompanies the Quarterly Report on Form 10-Q (the “Form 10-Q”) for the quarter ended March 31, 2007 of Crimson Exploration Inc. (the “Issuer”).  The undersigned hereby certifies that the Form 10-Q fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)) and that the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Issuer. 

 

| Date:

  | May 21, 2007

                   |   |
|---------------|---------------------------------------|--------|
| /s/           | Allan D. Keel                         |   |
| Name:         | Allan D. Keel                         |   |
| Title:        | President and Chief Executive Officer |   |
|          |                                  |   |
|          |                                  |   |

 

A signed original of this written statement required by Section 906 has been provided to the Issuer and will be furnished to the Securities and Exchange Commission, or its staff, upon request.
<TABLE> <S> <C>


<ARTICLE>                     7
<CIK>                         0000814181
<NAME>                        Penn Treaty American Corporation
<MULTIPLIER>                  1000

<S>                             <C>
<PERIOD-START>                  JAN-01-2000
<PERIOD-TYPE>                         3-MOS
<FISCAL-YEAR-END>               DEC-31-2000
<PERIOD-END>                    MAR-31-2000
<DEBT-HELD-FOR-SALE>                370,585
<DEBT-CARRYING-VALUE>                     0
<DEBT-MARKET-VALUE>                       0
<EQUITIES>                           20,626
<MORTGAGE>                                0
<REAL-ESTATE>                             0
<TOTAL-INVEST>                      391,369
<CASH>                               16,671
<RECOVER-REINSURE>                   15,028
<DEFERRED-ACQUISITION>              219,409
<TOTAL-ASSETS>                      731,795
<POLICY-LOSSES>                     295,293
<UNEARNED-PREMIUMS>                       0
<POLICY-OTHER>                      142,056
<POLICY-HOLDER-FUNDS>                     0
<NOTES-PAYABLE>                      82,024
<PREFERRED-MANDATORY>                     0
<PREFERRED>                               0
<COMMON>                                819
<OTHER-SE>                          163,252
<TOTAL-LIABILITY-AND-EQUITY>        731,795
<PREMIUMS>                           86,038
<INVESTMENT-INCOME>                   6,161
<INVESTMENT-GAINS>                    2,155
<OTHER-INCOME>                        2,138
<BENEFITS>                           59,911
<UNDERWRITING-AMORTIZATION>         (10,890)
<UNDERWRITING-OTHER>                 39,140
<INCOME-PRETAX>                       8,331
<INCOME-TAX>                          2,840
<INCOME-CONTINUING>                   5,491
<DISCONTINUED>                            0
<EXTRAORDINARY>                           0
<CHANGES>                                 0
<NET-INCOME>                          5,491
<EPS-BASIC>                            0.75
<EPS-DILUTED>                          0.64
<RESERVE-OPEN>                            0
<PROVISION-CURRENT>                       0
<PROVISION-PRIOR>                         0
<PAYMENTS-CURRENT>                        0
<PAYMENTS-PRIOR>                          0
<RESERVE-CLOSE>                           0
<CUMULATIVE-DEFICIENCY>                   0




</TABLE>
Exhibit 32

                  Certifications Pursuant to Section 906 of the
                               Sarbanes-Oxley Act







<PAGE>

                                   Exhibit 32
      CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER
                         OF KLAMATH FIRST BANCORP, INC.
            PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


In  connection  with the  Annual  Report of Klamath  First  Bancorp,  Inc.  (the
"Company")  on Form 10-K for the period ended  September  30, 2003 as filed with
the Securities and Exchange  Commission on the date hereof (the  "Report"),  the
undersigned hereby certify, pursuant to Section 906 of the Sarbanes-Oxley Act of
2002, that:

     1.   the Report fully complies with the  requirements of Sections 13(a) and
          15(d) of the Securities Exchange Act of 1934, as amended, and

     2.   the  information  contained  in the  report  fairly  presents,  in all
          material respects,  the Company's  financial  condition and results of
          operations.



_/s/ Kermit K. Houser_________________        _/s/ Marshall J. Alexander_______
Kermit K. Houser                              Marshall J. Alexander
Chief Executive Officer                       Chief Financial Officer

Dated: December 29, 2003

A signed  original of this  written  statement  required by Section 906 has been
provided to Klamath  First  Bancorp,  Inc. and will be retained by Klamath First
Bancorp,  Inc. and furnished to the  Securities  and Exchange  Commission or its
staff upon request.
§ 830.20 Requirements for a unique device identifier. A unique device identifier (UDI) must: ( a ) Be issued under a system operated by FDA or an FDA-accredited issuing agency;
( b ) Conform to each of the following international standards: ( 1 ) ISO/IEC 15459-2, which is incorporated by reference at § 830.10;
( 2 ) ISO/IEC 15459-4, which is incorporated by reference at § 830.10; and
( 3 ) ISO/IEC 15459-6, which is incorporated by reference at § 830.10.
( c ) Use only characters and numbers from the invariant character set of ISO/IEC 646, which is incorporated by reference at § 830.10.
[78 FR 58825, Sept. 24, 2013]
Editorial Note on Part 864
Editorial Note: Nomenclature changes to part 864 appear at 73 FR 35341, June 23, 2008.

§ 864.9575 Environmental chamber for storage of platelet concentrate. ( a ) *Identification.* An environmental chamber for storage of platelet concentrate is a device used to hold platelet-rich plasma within a preselected temperature range.
( b ) *Classification.* Class II (special controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 864.9.
[45 FR 60648, Sept. 12, 1980, as amended at 63 FR 59226, Nov. 3, 1998]
<TABLE> <S> <C>

<ARTICLE> 5

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-START>                             JAN-01-1999
<PERIOD-END>                               SEP-30-1999
<CASH>                                       5,063,442
<SECURITIES>                                         0
<RECEIVABLES>                                1,805,799
<ALLOWANCES>                                    10,000
<INVENTORY>                                  2,460,797
<CURRENT-ASSETS>                             9,804,483
<PP&E>                                      89,484,938
<DEPRECIATION>                            (11,340,638)
<TOTAL-ASSETS>                              88,579,080<F1>
<CURRENT-LIABILITIES>                        6,619,495
<BONDS>                                      7,537,500
<PREFERRED-MANDATORY>                       16,043,955
<PREFERRED>                                          0
<COMMON>                                        38,439
<OTHER-SE>                                  56,439,180
<TOTAL-LIABILITY-AND-EQUITY>                88,579,080
<SALES>                                     24,144,861<F2>
<TOTAL-REVENUES>                            24,144,861<F2>
<CGS>                                       16,736,245
<TOTAL-COSTS>                               25,050,465
<OTHER-EXPENSES>                               112,001<F3>
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                             391,527
<INCOME-PRETAX>                            (1,409,132)
<INCOME-TAX>                                 (493,205)
<INCOME-CONTINUING>                          (915,927)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 (915,927)
<EPS-BASIC>                                   (0.12)
<EPS-DILUTED>                                   (0.12)
<FN>
<F1>Total Assets includes Assets Held for Sale of $38,549.
<F2>Sales and Total Revenues are net of federal and state excise taxes.
<F3>Includes a $260,000 non-cash loss related to a keg exchange.
</FN>


</TABLE>
# C_2014315EN.01003702.xml

| 15.9.2014 | EN | Official Journal of the European Union | C 315/37 |
| --- | --- | --- | --- |

15.9.2014

EN

Official Journal of the European Union

C 315/37

---

Request for a preliminary ruling from the Finanzgericht Hamburg (Germany) lodged on 16 June 2014 — ADM Hamburg AG v Hauptzollamt Hamburg-Stadt

(Case C-294/14)

2014/C 315/60

Language of the case: German

Referring court

Referring court

Finanzgericht Hamburg

Parties to the main proceedings

Parties to the main proceedings

Applicant: ADM Hamburg AG

Applicant:

Defendant: Hauptzollamt Hamburg-Stadt

Defendant:

Question referred

Question referred

Is the factual condition laid down in the first sentence of Article 74(1) of Commission Regulation (EEC) No 2454/93 of 2 July 1993 laying down provisions for the implementation of Council Regulation (EEC) No 2913/92 (1) establishing the Community Customs Code, as amended by Commission Regulation (EU) No 1063/2010 of 18 November 2010, (2) whereby the products declared for release for free circulation in the European Union must be the same products as exported from the beneficiary country in which they are considered to originate, fulfilled in a case such as the present case, where several part-consignments of crude palm kernel oil are exported from different GSP exporting countries from those in which they are considered to originate and imported into the European Union not as physically separate consignments, but are all exported after being poured into the same tank of the cargo vessel and imported as a mixture in that tank into the European Union, such that it can be ruled out that other products (not enjoying preferential treatment) have been put into the tank of the cargo vessel during the time the products were being transported until they were released for free circulation?

1

2

---

(1)  OJ 1993 L 253, p. 1.

1

(2)  OJ 2010 L 307, p. 1.

2

---
UNITED STATES NAVY–MARINE CORPS

COURT OF CRIMINAL APPEALS

_________________________

No. 201600290

_________________________

UNITED STATES OF AMERICA

Appellee

v.

FRANK L. SPEARS

Petty Officer First Class (E-6), U.S. Navy

Appellant

_________________________

Appeal from the United States Navy-Marine Corps Trial Judiciary

Military Judge: Captain Paul C. LeBlanc, JAGC, USN.

For Appellant: Commander Chris D. Tucker, JAGC, USN.

For Appellee: Brian K. Keller, Esq.

_________________________

Decided 30 November 2016

_________________________

Before PALMER, CAMPBELL, and RUGH, Appellate Military Judges

_________________________

After careful consideration of the record, submitted without assignment of 

error, we affirm the findings and sentence as approved by the convening 

authority. Art. 66(c), Uniform Code of Military Justice, 10 U.S.C. § 866(c). 

For the Court

R.H. TROIDL

Clerk of Court
Exhibit 32.1

# Written Statement of
the Chief Executive Officer and Chief Financial OfficerPursuant to 18 U.S.C. §1350

Solely
for the purposes of complying with 18 U.S.C. §1350, as adopted pursuant to Section
906 of the Sarbanes-Oxley Act of 2002, we, the undersigned President and Chief Executive
Officer and Vice President Law/Finance and Secretary of Ladish Co., Inc. (the
Company), hereby certify, based on our knowledge, that the Quarterly Report on
Form 10-Q of the Company for the quarter ended June 30, 2005 (the Report)
fully complies with the requirements of Section 13(a) of the Securities Exchange Act of
1934 and that information contained in the Report fairly presents, in all material
respects, the financial condition and results of operations of the Company.

/s/ Kerry L. Woody
Kerry L. Woody
President and Chief
Executive Officer

/s/ Wayne E. Larsen
Wayne E. Larsen
Vice President
Law/Finance & Secretary

July 26, 2005